Literature DB >> 30404037

Obliterative Portal Venopathy Without Cirrhosis Is Prevalent in Pediatric Cystic Fibrosis Liver Disease With Portal Hypertension.

Hao Wu1, Megan Vu2, Sadhna Dhingra3, Ruth Ackah2, John A Goss2, Abbas Rana2, Norma Quintanilla4, Kalyani Patel4, Daniel H Leung5.   

Abstract

Cystic fibrosis liver disease (CFLD) has long been postulated to be secondary to dysfunctional cystic fibrosis transmembrane conductance regulator in the apical biliary epithelium, leading to bile stasis and eventually cirrhosis with portal hypertension. However, pathologic changes in the cystic fibrosis (CF) liver are distinct from the pancreas and lungs in that fibrocystic changes are absent.1,2 Furthermore, the lack of clinically evident biliary obstruction and liver dysfunction suggest there may be alternative mechanisms that contribute to CFLD. Two recent studies in young adults described obliterative portal venopathy (OPV) and noncirrhotic portal hypertension (NCPH) as the predominant pathophysiology in young adults (median, 22 y) with CFLD.3,4 It is unknown if OPV develops early in childhood. Herein, we report the clinical features and liver pathology in 17 explants from children and adolescents with CF, representing 13.6% (17 of 125) of the CF liver transplant population in the United States according to the United Network for Organ Sharing and Organ Procurement and Transplantation Network.
Copyright © 2019 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Year:  2018        PMID: 30404037     DOI: 10.1016/j.cgh.2018.10.046

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  7 in total

1.  Role of transient elastography and APRI in the assessment of pediatric cystic fibrosis liver disease.

Authors:  Jessica P Woolfson; Richard A Schreiber; Shraavan Raveendran; Mark Chilvers; Collin Barker; Orlee R Guttman
Journal:  Can Liver J       Date:  2021-02-24

2.  Characteristics and Outcomes of Children With Cystic Fibrosis Hospitalized With Cirrhosis in the United States.

Authors:  Christina Thornton; Ranjani Somayaji; Michael Parkins; Mark G Swain; Kathleen J Ramos; Christopher H Goss; Abdel A Shaheen
Journal:  Am J Gastroenterol       Date:  2021-08-01       Impact factor: 12.045

Review 3.  Diagnostic challenges in non-cirrhotic portal hypertension - porto sinusoidal vascular disease.

Authors:  Oana Nicoară-Farcău; Ioana Rusu; Horia Stefănescu; Marcel Tanțău; Radu Ion Badea; Bogdan Procopeț
Journal:  World J Gastroenterol       Date:  2020-06-14       Impact factor: 5.742

4.  Association Between Transient Elastography and Controlled Attenuated Parameter and Liver Ultrasound in Children With Cystic Fibrosis.

Authors:  Wen Ye; Daniel H Leung; Jean P Molleston; Simon C Ling; Karen F Murray; Jennifer L Nicholas; Suiyuan Huang; Boaz W Karmazyn; Roger K Harned; Prakash Masand; Adina L Alazraki; Oscar M Navarro; Randolph K Otto; Joseph J Palermo; Alexander J Towbin; Estella M Alonso; Wikrom W Karnsakul; Sarah Jane Schwarzenberg; Glenn F Seidel; Marilyn Siegel; John C Magee; Michael R Narkewicz; A Jay Freeman
Journal:  Hepatol Commun       Date:  2021-05-13

5.  Cystic fibrosis related liver disease and endocrine considerations.

Authors:  Jordan S Sherwood; Jagdeesh Ullal; Katherine Kutney; Kara S Hughan
Journal:  J Clin Transl Endocrinol       Date:  2021-12-13

Review 6.  Understanding Cystic Fibrosis Comorbidities and Their Impact on Nutritional Management.

Authors:  Dhiren Patel; Albert Shan; Stacy Mathews; Meghana Sathe
Journal:  Nutrients       Date:  2022-02-28       Impact factor: 5.717

Review 7.  Current Treatment Options for Cystic Fibrosis-Related Liver Disease.

Authors:  Katharina Staufer
Journal:  Int J Mol Sci       Date:  2020-11-14       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.